Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
Aharona Glatman‐Freedman, Yael Hershkovitz, Zalman Kaufman, Rita Dichtiar, Lital Keinan‐Boker, Michal Bromberg
Abstract
In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting.
Topics & Concepts
OutbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineCoronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakPopulationCoronavirusEnvironmental healthDiseaseInternal medicineInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies